Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody ...
South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...
The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...
Private biotech company Dren Bio has entered into a strategic collaboration with French drugmaker Sanofi to develop therapies ...
Sanofi bought Dren’s DR-0201 program earlier this year for $600 million upfront and is running two Phase I trials in ...
Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...
French pharmaceutical group Sanofi said on Monday the U.S. Food and Drug Administration's decision on its investigative drug ...
Tolebrutinib, which Sanofi acquired in a $3.7 billion buyout, failed a Phase 3 study in “primary progressive” multiple ...
So continues the rocky path for the drug, which Sanofi picked up in its $3.7 billion buyout of Principia Biopharma back in ...
Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback